Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:PRAX 16 October 2025 - 14 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Shares of Praxis Precision Medicines rose about 8% to $303.23 by mid-afternoon Wednesday after the company named epilepsy specialist Dr. Orrin Devinsky as head of clinical strategy. Investors are watching two FDA drug applications set for mid-February. Praxis recently raised $575 million in a public offering. The broader biotech sector outperformed the market, while major indexes fell.
14 January 2026
·
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines shares traded near $265 on December 9, 2025, up over 500% in three months and close to a 52-week high of $278, giving the company a $6.6 billion market cap. The surge followed positive Phase 3 results for ulixacaltamide in essential tremor, new bullish analyst targets, and increased volatility after a short-seller attack.
9 December 2025
·
Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines shares surged 30.5% to close at $247.99 on December 5, hitting a new 52-week high after positive epilepsy trial results and a favorable FDA pre-NDA meeting. The company’s market cap reached about $6.2 billion. PRAX stock has gained over 500% in three years but remains down 72% over five years. Wall Street sentiment is mostly positive, though some skepticism remains.
6 December 2025
·
Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Treasure Global (NASDAQ:TGL) surged about 276% on December 5, 2025, after a 1-for-20 reverse stock split and news of an acquisition. SMX (NASDAQ:SMX) jumped 135%, and Wheeler Real Estate Investment Trust (NASDAQ:WHLR) gained 98%. The S&P 500, Nasdaq 100, and Dow all closed higher, but small- and mid-cap stocks saw the largest percentage moves.
6 December 2025
············
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines shares traded around $189.97 early December 5 after surging on positive FDA feedback for its essential tremor drug and new data in rare epilepsies. The stock swung between $180.25 and $305.55 intraday, with a market cap near $1.1 billion. PRAX has gained over 1,700% in 12 months, but remains volatile amid short-seller pressure and ongoing losses.
5 December 2025
·
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares soared 183% to $162.71 on Thursday after its drug ulixacaltamide met all key goals in a Phase 3 trial for essential tremor. The results showed significant improvement in patient function and no serious side effects. The company plans to seek FDA approval by early 2026 and launched a public stock offering to fund commercialization.
17 October 2025
·
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··

Stock Market Today

  • Eastern Platinum (TSE:ELR) Surges Above 200-Day Moving Average
    April 9, 2026, 4:13 AM EDT. Eastern Platinum Limited (TSE:ELR) stock crossed above its 200-day moving average, hitting a high of C$0.51 on Wednesday, signaling potential bullish momentum. The 200-day moving average is a key technical indicator used to assess long-term price trends. Shares last traded at C$0.46 with a volume of 273,276. The company has a market cap of C$92.59 million but reported a quarterly loss with earnings per share (EPS) of -C$0.05 and a negative return on equity of 27.28%. Despite current challenges, Eastern Platinum engages in platinum group metal mining in South Africa. Analyst ratings remain Hold, with forecasts of continued negative EPS for the fiscal year. The stock's price action above this technical support level may attract renewed investor interest amid mixed fundamentals.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 4:14 AM EDT Exchange Income Stock Surpasses 200-Day Moving Average Amid Upgraded Price Targets April 9, 2026, 4:14 AM EDT. Exchange Income Co. (TSE:EIF) stock crossed above its 200-day moving average of C$88.10, reaching as high as C$107.75 in recent trading. The firm's shares last traded at C$105.00 with over 204,000 shares changing hands. Multiple analysts have raised their price targets, including Scotiabank's upgrade to C$129.00 and Ventum Financial's to C$135.00, reflecting strong consensus optimism with a 'Buy' rating and an average target price of C$115.04. The company
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop